Liquidia (NASDAQ:LQDA) Insider Sarah Krepp Sells 13,165 Shares

13 Jan 2026, 22:18 by Michael Walen · The Markets Daily

Liquidia Corporation (NASDAQ:LQDA – Get Free Report) insider Sarah Krepp sold 13,165 shares of Liquidia stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $37.43, for a total value of $492,765.95. Following the completion of the transaction, the insider owned 140,769 shares in the company, valued at approximately $5,268,983.67. This represents a 8.55% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Sarah Krepp also recently made the following trade(s):

On Monday, December 1st, Sarah Krepp sold 221 shares of Liquidia stock. The stock was sold at an average price of $32.19, for a total transaction of $7,113.99.

Liquidia Trading Up 4.1%

Shares of NASDAQ LQDA traded up $1.49 during mid-day trading on Tuesday, hitting $38.09. The stock had a trading volume of 2,055,159 shares, compared to its average volume of 2,814,845. The business has a 50 day moving average price of $31.94 and a two-hundred day moving average price of $25.40. Liquidia Corporation has a 1 year low of $11.26 and a 1 year high of $39.29. The company has a debt-to-equity ratio of 6.19, a quick ratio of 1.96 and a current ratio of 2.20. The firm has a market cap of $3.31 billion, a P/E ratio of -26.45, a price-to-earnings-growth ratio of 1.19 and a beta of 0.48.

Liquidia (NASDAQ:LQDA – Get Free Report) last released its quarterly earnings data on Monday, November 3rd. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.41. The business had revenue of $54.34 million during the quarter, compared to analysts’ expectations of $18.86 million. Liquidia had a negative return on equity of 296.78% and a negative net margin of 176.04%.The business’s revenue for the quarter was up 1106.7% on a year-over-year basis. On average, equities analysts anticipate that Liquidia Corporation will post -1.51 EPS for the current fiscal year.

Hedge Funds Weigh In On Liquidia

Institutional investors and hedge funds have recently modified their holdings of the stock. Skandinaviska Enskilda Banken AB publ bought a new position in Liquidia in the 3rd quarter worth about $30,000. FNY Investment Advisers LLC bought a new stake in Liquidia during the 3rd quarter valued at about $34,000. NewEdge Advisors LLC purchased a new position in Liquidia in the second quarter worth about $25,000. Steward Partners Investment Advisory LLC lifted its stake in shares of Liquidia by 24.0% in the second quarter. Steward Partners Investment Advisory LLC now owns 6,200 shares of the company’s stock worth $77,000 after buying an additional 1,200 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in shares of Liquidia by 281.2% in the second quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company’s stock worth $83,000 after buying an additional 4,927 shares in the last quarter. 64.54% of the stock is currently owned by institutional investors.

Liquidia News Summary

Here are the key news stories impacting Liquidia this week:

Positive Sentiment: Short interest fell materially in December — short interest declined 18.1% to 10,709,682 shares as of Dec. 31 (about 17.6% of shares were sold short) and the days-to-cover was ~11.6. Fewer active shorts can reduce downside pressure and may have contributed to the stock moving higher. (Market data entry)
Neutral Sentiment: January short-interest data shows 0 shares as of Jan. 12 — this is almost certainly a reporting or data glitch rather than a real liquidation of all short positions. Investors should monitor the next short-interest report for a corrected figure. (Market data entry)
Negative Sentiment: CEO Roger Jeffs sold 66,610 shares at an average $37.43 (≈$2.49M); his stake decreased ~6.03%. This large insider sale may be seen as a negative signal by some investors. SEC Filing
Negative Sentiment: CFO Michael Kaseta sold 36,932 shares at $37.43 (≈$1.38M); his holding fell ~9.52%. SEC Filing
Negative Sentiment: General Counsel Russell Schundler sold 27,289 shares at $37.43 (≈$1.02M); his holding fell ~4.50%. SEC Filing
Negative Sentiment: Other insiders (including Rajeev Saggar, Jason Adair, Scott Moomaw, Sarah Krepp, CAO Dana Boyle) also executed sales on Jan. 12 at ~$37.43 per share, each reducing positions between ~6–11.7%. These combined sales represent significant insider liquidity taken at current prices. Rajeev Saggar SEC Filing Dana Boyle SEC Filing Jason Adair SEC Filing Scott Moomaw SEC Filing Sarah Krepp SEC Filing

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Wells Fargo & Company initiated coverage on shares of Liquidia in a research note on Monday, October 20th. They set an “overweight” rating and a $31.00 target price on the stock. Raymond James Financial reaffirmed a “strong-buy” rating and set a $47.00 price objective on shares of Liquidia in a research report on Tuesday, November 4th. HC Wainwright upped their target price on Liquidia from $35.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Needham & Company LLC raised their target price on Liquidia from $36.00 to $52.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Finally, Jefferies Financial Group lifted their price target on Liquidia from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Liquidia currently has an average rating of “Moderate Buy” and an average target price of $39.67.

View Our Latest Stock Report on LQDA

Liquidia Company Profile

(Get Free Report)

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.